Scilex Holding Company Set to Present at Major Investment Conference
PALO ALTO, Calif. -- Scilex Holding Company (Nasdaq: SCLX), a leader in innovative, non-opioid solutions for pain management, is gearing up to make a notable impression at the 26th Annual H.C. Wainwright Global Investment Conference. The presentation will be led by Jaisim Shah, the Chief Executive Officer and President of Scilex, and is expected to attract the interest of both investors and healthcare professionals.
Presentation Details
Date and Location
The conference is set to take place from September 9-11, 2024, at the esteemed Lotte NY Palace Hotel in New York City. Scilex's presentation is scheduled for September 11, from 8:00 to 8:30 AM ET, during which they will share important updates and outline their future strategies.
Scilex: Pioneering Pain Management
Scilex Holding Company is dedicated to transforming pain management through a variety of innovative products. Their proprietary offerings include ZTlido®, ELYXYB®, and Gloperba®. ZTlido® is a topical lidocaine product designed to alleviate neuropathic pain related to postherpetic neuralgia. ELYXYB® is a groundbreaking ready-to-use oral solution for treating acute migraines, while Gloperba® is a liquid formulation of colchicine aimed at preventing gout flare-ups.
Transforming Treatment Approaches
Current and Upcoming Product Candidates
Scilex is actively advancing its pipeline with three promising candidates. SP-102 (SEMDEXA™) is a viscous gel intended for treating lumbosacral radicular pain and has received Fast Track designation from the FDA. Similarly, SP-103 is a next-generation, triple-strength lidocaine formulation targeting chronic neck pain, and SP-104 is a novel low-dose naltrexone aimed at treating fibromyalgia.
Dedication to Innovation
Scilex Holding Company is steadfast in its commitment to developing non-opioid therapies that address unmet medical needs and improve patient outcomes. The team is consistently exploring new therapeutic options to manage pain effectively in both acute and chronic situations with care and expertise.
Engaging with Scilex
Scilex is eager to connect with investors and other interested parties, welcoming inquiries about their advancements and potential. Their focus remains on transparency and fostering ongoing engagement within the health management community.
Frequently Asked Questions
What is the purpose of Scilex Holding Company's presentation at the conference?
The presentation aims to highlight Scilex’s innovative products and discuss future strategies in the non-opioid pain management sector.
When and where is the conference taking place?
The conference will occur from September 9-11, 2024, at the Lotte NY Palace Hotel in New York City.
What products does Scilex currently offer?
Scilex offers ZTlido®, ELYXYB®, and Gloperba®, which address pain management for various medical conditions.
What are the new product candidates Scilex is developing?
Scilex is developing SP-102 (SEMDEXA™), SP-103, and SP-104, each targeting different types of pain and conditions.
How can investors reach out to Scilex Holding Company?
Investors can contact Scilex via their official email at info@scilexholding.com or visit their website for additional information.